Aripiprazole tablets recalled due to manufacturing process deviations
Accord Healthcare is recalling 747,464 bottles of Aripiprazole 2mg tablets due to manufacturing process deviations discovered during an FDA inspection. The affected medication was distributed in the United States, Puerto Rico, and Canada.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall due to manufacturing process deviations, which by definition indicates potential for adverse health consequences. No illnesses, injuries, or deaths have been reported in the source text, placing this in the risk-of-harm category without documented adverse consequences.
Plain-English summary
Accord Healthcare, Inc. is recalling Aripiprazole 2mg tablets distributed in the United States, Puerto Rico, and Canada. A total of 747,464 bottles are affected.
The recall was initiated following the identification of Current Good Manufacturing Practice (CGMP) deviations during an FDA inspection. These deviations indicate that the manufacturing facility did not meet the required pharmaceutical quality standards and manufacturing control procedures established by the FDA.
Affected products include tablets packaged in 30-count bottles (NDC 16729-278-10) and 100-count bottles (NDC 16729-278-01), manufactured by Intas Pharmaceuticals Limited in Ahmedabad, India for Accord Healthcare, Inc. Multiple batches with expiration dates ranging from September 2023 through May 2025 are included in this recall, with batch numbers including P2005474, P2100001, P2100789, P2100790, P2101319, P2102147, P2102148, P2104084, P2105410, P2107233, P2105411, P2106671, P2106673, P2106675, P2200428, P2200429, P2200430, P2203333, P2203334, P2102940, and P2105793.
Patients taking this medication should contact their healthcare provider or pharmacist to determine if their prescription may be affected and what actions to take. Do not discontinue use of this medication abruptly without medical guidance, as sudden stopping could lead to serious adverse effects. Return affected medication to a pharmacy for proper disposal.
The recalled product
- Product
- ARIPIPRAZOLE (ARIPIPRAZOLE)
- Brand
- ARIPIPRAZOLE
- Manufacturer
- Accord Healthcare, Inc.
- Category
- Drug
- Hazard
- manufacturing-deviation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Batches: a) P2005474
- Exp 9/30/2023
- P2100001
- Exp 12/31/2023
- P2100789
- P2100790
- Exp 1/31/2024
- P2101319
- Exp 2/28/2024
- P2102147
- P2102148
- Exp 3/31/2024
- P2104084
- Exp 6/30/2024
- P2105410
- P2107233
- P2105411
- Exp 7/31/2024
- P2106671
- P2106673
UPCs (1)
- 316729278102
Distribution
Distribution scope not specified by the agency.
Related recalls
Same brand · ARIPIPRAZOLE
- HighAripiprazole tablets recalled nationwide due to excess active ingredient
FDA (Drugs) · 2025-09-24
- ModeratePrescription Aripiprazole tablets recalled nationwide for storage temperature deviation
FDA (Drugs) · 2024-01-03
- HighAntipsychotic Drug Recalled for Failed Quality Control Test
FDA (Drugs) · 2023-04-26
- ModeratePrescription drug aripiprazole tablets recalled for manufacturing practice deviations
FDA (Drugs) · 2023-03-08
- ModerateAripiprazole Tablets Recalled Following FDA Inspection for Manufacturing Deviations
FDA (Drugs) · 2023-03-08
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27